How to Use a Noninferiority Trial Users' Guides to the Medical Literature

被引:72
作者
Mulla, Sohail M. [1 ]
Scott, Ian A. [3 ]
Jackevicius, Cynthia A. [4 ,5 ,6 ,7 ,8 ]
You, John J. [1 ,2 ,4 ]
Guyatt, Gordon H. [1 ,2 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
[2] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada
[3] Princess Alexandra Hosp, Dept Internal Med & Clin Epidemiol, Brisbane, Qld 4102, Australia
[4] Inst Clin Evaluat Sci, Toronto, ON, Canada
[5] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA
[6] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[7] Univ Hlth Network, Toronto, ON, Canada
[8] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 308卷 / 24期
关键词
ATRIAL-FIBRILLATION; NON-INFERIORITY; OPEN-LABEL;
D O I
10.1001/2012.jama.11235
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical investigators are increasingly testing treatments that have the primary benefit of decreased burden or harms relative to an existing standard. The goal of the resulting randomized trials-called noninferiority trials-is to establish that the novel treatment's effectiveness is not substantially less than the existing standard. Conclusions from these trials are, however, based on noninferiority thresholds specified by authors whose judgments may not coincide with those of patients and clinicians. This article highlights issues related to validity, interpretation, and applicability of results specific to noninferiority trials. Suboptimal administration of standard treatment or exclusive reliance on the analyze-as-randomized approach that is standard for conventional superiority trials may produce misleading results in noninferiority trials. Clinicians should judge whether the novel treatment's impact on effectiveness outcomes-the prime reason for wanting to prescribe it-is sufficiently close to that of standard treatment that they are comfortable substituting it for the existing standard. Trading off desirable and undesirable consequences is an individual decision: given the benefits of a novel treatment, some patients may perceive the uncertainty regarding a reduction in treatment effectiveness as acceptable while others may not. JAMA 2012;308(24):2605-2611
引用
收藏
页码:2605 / 2611
页数:7
相关论文
共 21 条
[1]   Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial [J].
Aujesky, Drahomir ;
Roy, Pierre-Marie ;
Verschuren, Franck ;
Righini, Marc ;
Osterwalder, Joseph ;
Egloff, Michael ;
Renaud, Bertrand ;
Verhamme, Peter ;
Stone, Roslyn A. ;
Legal, Catherine ;
Sanchez, Olivier ;
Pugh, Nathan A. ;
N'gako, Alfred ;
Cornuz, Jacques ;
Hugii, Olivier ;
Beer, Hans-Juerg ;
Perrier, Arnaud ;
Fine, Michael J. ;
Yealy, Donald M. .
LANCET, 2011, 378 (9785) :41-48
[2]   Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations [J].
Fleming, Thomas R. ;
Emerson, Scott S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (17) :1557-1559
[3]   Current issues in non-inferiority trials [J].
Flerning, Thomas R. .
STATISTICS IN MEDICINE, 2008, 27 (03) :317-332
[4]   Lessons from and cautions about noninferiority and equivalence randomized trials [J].
Gotzsche, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (10) :1172-1174
[5]   Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].
Granger, Christopher B. ;
Alexander, John H. ;
McMurray, John J. V. ;
Lopes, Renato D. ;
Hylek, Elaine M. ;
Hanna, Michael ;
Al-Khalidi, Hussein R. ;
Ansell, Jack ;
Atar, Dan ;
Avezum, Alvaro ;
Cecilia Bahit, M. ;
Diaz, Rafael ;
Easton, J. Donald ;
Ezekowitz, Justin A. ;
Flaker, Greg ;
Garcia, David ;
Geraldes, Margarida ;
Gersh, Bernard J. ;
Golitsyn, Sergey ;
Goto, Shinya ;
Hermosillo, Antonio G. ;
Hohnloser, Stefan H. ;
Horowitz, John ;
Mohan, Puneet ;
Jansky, Petr ;
Lewis, Basil S. ;
Luis Lopez-Sendon, Jose ;
Pais, Prem ;
Parkhomenko, Alexander ;
Verheugt, Freek W. A. ;
Zhu, Jun ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992
[6]   Users' Guides to The Medical Literature - XXV. Evidence-based medicine: Principles for applying the Users' Guides to patient care [J].
Guyatt, GH ;
Haynes, RB ;
Jaeschke, RZ ;
Cook, DJ ;
Green, L ;
Naylor, CD ;
Wilson, MC ;
Richardson, WS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (10) :1290-1296
[7]   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis [J].
Hart, RG ;
Benavente, O ;
McBride, R ;
Pearce, LA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :492-+
[8]   Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005 [J].
Jackson, Kevin ;
Gersh, Bernard J. ;
Stockbridge, Norman ;
Fleming, Thomas R. ;
Temple, Robert ;
Califf, Robert M. ;
Connolly, Stuart J. ;
Wallentin, Lars ;
Granger, Christopher B. .
AMERICAN HEART JOURNAL, 2008, 155 (05) :829-840
[9]   Good enough: A primer on the analysis and interpretation of noninferiority trials [J].
Kaul, Sanjay ;
Diamond, George A. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (01) :62-69
[10]   Which patients to include in the analysis? [J].
Kunz, R ;
Guyatt, G .
TRANSFUSION, 2006, 46 (06) :881-884